Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Cash & Equivalents (2017 - 2025)

Historic Cash & Equivalents for Aclaris Therapeutics (ACRS) over the last 9 years, with Q3 2025 value amounting to $25.3 million.

  • Aclaris Therapeutics' Cash & Equivalents fell 4699.8% to $25.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.3 million, marking a year-over-year decrease of 4699.8%. This contributed to the annual value of $24.6 million for FY2024, which is 3838.71% down from last year.
  • As of Q3 2025, Aclaris Therapeutics' Cash & Equivalents stood at $25.3 million, which was down 4699.8% from $25.4 million recorded in Q2 2025.
  • Aclaris Therapeutics' 5-year Cash & Equivalents high stood at $113.4 million for Q2 2021, and its period low was $22.8 million during Q2 2024.
  • In the last 5 years, Aclaris Therapeutics' Cash & Equivalents had a median value of $36.3 million in 2022 and averaged $42.5 million.
  • Per our database at Business Quant, Aclaris Therapeutics' Cash & Equivalents soared by 24813.58% in 2021 and then crashed by 5436.83% in 2023.
  • Aclaris Therapeutics' Cash & Equivalents (Quarter) stood at $27.3 million in 2021, then skyrocketed by 65.55% to $45.3 million in 2022, then decreased by 11.92% to $39.9 million in 2023, then tumbled by 38.39% to $24.6 million in 2024, then increased by 2.79% to $25.3 million in 2025.
  • Its Cash & Equivalents stands at $25.3 million for Q3 2025, versus $25.4 million for Q2 2025 and $30.4 million for Q1 2025.